Table of Contents Author Guidelines Submit a Manuscript
Neurology Research International
Volume 2012 (2012), Article ID 454957, 13 pages
http://dx.doi.org/10.1155/2012/454957
Review Article

The Clinical and Prognostic Significance of Activated AKT-mTOR Pathway in Human Astrocytomas

1First Department of Pathology, Laiko Hospital, National and Kapodistrian University of Athens Medical School, 11527 Athens, Greece
2Department of Biological Chemistry, National and Kapodistrian University of Athens Medical School, 11527 Athens, Greece

Received 30 July 2011; Revised 5 December 2011; Accepted 9 December 2011

Academic Editor: Stuart Burri

Copyright © 2012 Elias A. El Habr et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. N. Louis, H. Ohgaki, O. D. Wiestler et al., “The 2007 WHO classification of tumours of the central nervous system,” Acta Neuropathologica, vol. 114, no. 2, pp. 97–109, 2007. View at Publisher · View at Google Scholar · View at PubMed
  2. J. W. Mandell, “Immunohistochemical assessment of protein phosphorylation state: the dream and the reality,” Histochemistry and Cell Biology, vol. 130, no. 3, pp. 465–471, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. J. LoPiccolo, G. M. Blumenthal, W. B. Bernstein, and P. A. Dennis, “Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations,” Drug Resistance Updates, vol. 11, no. 1-2, pp. 32–50, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. J. A. Engelman, J. Luo, and L. C. Cantley, “The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism,” Nature Reviews Genetics, vol. 7, no. 8, pp. 606–619, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. K. E. Anderson, J. Coadwell, L. R. Stephens, and P. T. Hawkins, “Translocation of PDK-1 to the plasma membrane is important in allowing PDK-1 to activate protein kinase B,” Current Biology, vol. 8, no. 12, pp. 684–691, 1998. View at Google Scholar · View at Scopus
  6. E. M. Sale and G. J. Sale, “Protein kinase B: signalling roles and therapeutic targeting,” Cellular and Molecular Life Sciences, vol. 65, no. 1, pp. 113–127, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. G. V. Thomas, “mTOR and cancer: reason for dancing at the crossroads?” Current Opinion in Genetics and Development, vol. 16, no. 1, pp. 78–84, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. N. Hay and N. Sonenberg, “Upstream and downstream of mTOR,” Genes and Development, vol. 18, no. 16, pp. 1926–1945, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. A. C. Gingras, S. P. Gygi, B. Raught et al., “Regulation of 4E-BP1 phosphorylation: a novel two step mechanism,” Genes and Development, vol. 13, no. 11, pp. 1422–1437, 1999. View at Google Scholar · View at Scopus
  10. A. de Benedetti and J. R. Graff, “eIF-4E expression and its role in malignancies and metastases,” Oncogene, vol. 23, no. 18, pp. 3189–3199, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. M. A. Bjornsti and P. J. Houghton, “The TOR pathway: a target for cancer therapy,” Nature Reviews Cancer, vol. 4, no. 5, pp. 335–348, 2004. View at Google Scholar · View at Scopus
  12. J. Yang, D. Liao, Z. Wang, F. Liu, and G. Wu, “Mammalian target of rapamycin signaling pathway contributes to glioma progression and patients' prognosis,” Journal of Surgical Research, 2009. View at Publisher · View at Google Scholar · View at PubMed
  13. A. A. Saetta, G. Levidou, E. A. El-Habr et al., “Expression of pERK and pAKT in human astrocytomas: correlation with IDH1-R132H presence, vascular endothelial growth factor, microvascular characteristics and clinical outcome,” Virchows Archiv, vol. 458, no. 6, pp. 749–759, 2011. View at Publisher · View at Google Scholar · View at PubMed
  14. X. Y. Li, L. Q. Zhang, X. G. Zhang et al., “Association between AKT/mTOR signalling pathway and malignancy grade of human gliomas,” Journal of Neuro-Oncology, pp. 1–6, 2010. View at Publisher · View at Google Scholar · View at PubMed
  15. E. A. El-Habr, P. Tsiorva, M. Theodorou et al., “Analysis of PIK3CA and B-RAF gene mutations in human astrocytomas: association with activation of ERK and AKT,” Clinical Neuropathology, vol. 29, no. 4, pp. 239–245, 2010. View at Google Scholar
  16. G. Wang, C. Kang, and P. Pu, “Increased expression of Akt2 and activity of PI3K and cell proliferation with the ascending of tumor grade of human gliomas,” Clinical Neurology and Neurosurgery, vol. 112, no. 4, pp. 324–327, 2010. View at Publisher · View at Google Scholar · View at PubMed
  17. Y. Suzuki, K. Shirai, K. Oka et al., “Higher pakt expression predicts a significant worse prognosis in glioblastomas,” Journal of Radiation Research, vol. 51, no. 3, pp. 343–348, 2010. View at Publisher · View at Google Scholar
  18. L. Annovazzi, M. Mellai, V. Caldera, G. Valente, L. Tessitore, and D. Schiffer, “mTOR, S6 and AKT expression in relation to proliferation and apoptosis/autophagy in glioma,” Anticancer Research, vol. 29, no. 8, pp. 3087–3094, 2009. View at Google Scholar
  19. T. Matsutani, Y. Nagai, S. Mine, H. Murai, N. Saeki, and Y. Iwadate, “Akt/protein kinase B overexpression as an accurate prognostic marker in adult diffuse astrocytoma,” Acta Neurochirurgica, vol. 151, no. 3, pp. 263–268, 2009. View at Publisher · View at Google Scholar · View at PubMed
  20. A. Hlobilkova, J. Ehrmann, E. Sedlakova et al., “Could changes in the regulation of the PI3K/PKB/Akt signaling pathway and cell cycle be involved in astrocytic tumor pathogenesis and progression?” Neoplasma, vol. 54, no. 4, pp. 334–341, 2007. View at Google Scholar
  21. M. Mizoguchi, R. A. Betensky, T. T. Batchelor, D. C. Bernay, D. N. Louis, and C. L. Nutt, “Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival,” Journal of Neuropathology and Experimental Neurology, vol. 65, no. 12, pp. 1181–1188, 2006. View at Publisher · View at Google Scholar · View at PubMed
  22. C. E. Pelloski, E. Lin, L. Zhang et al., “Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma,” Clinical Cancer Research, vol. 12, no. 13, pp. 3935–3941, 2006. View at Publisher · View at Google Scholar · View at PubMed
  23. M. J. Riemenschneider, R. A. Betensky, S. M. Pasedag, and D. N. Louis, “AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling,” Cancer Research, vol. 66, no. 11, pp. 5618–5623, 2006. View at Publisher · View at Google Scholar · View at PubMed
  24. H. Wang, H. Wang, W. Zhang, H. J. Huang, W. S. L. Liao, and G. N. Fuller, “Analysis of the activation status of Akt, NFκB, and Stat3 in human diffuse gliomas,” Laboratory Investigation, vol. 84, no. 8, pp. 941–951, 2004. View at Publisher · View at Google Scholar · View at PubMed
  25. A. Chakravarti, G. Zhai, Y. Suzuki et al., “The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas,” Journal of Clinical Oncology, vol. 22, no. 10, pp. 1926–1933, 2004. View at Publisher · View at Google Scholar · View at PubMed
  26. G. Choe, S. Horvath, T. F. Cloughesy et al., “Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo,” Cancer Research, vol. 63, no. 11, pp. 2742–2746, 2003. View at Google Scholar
  27. T. F. Franke, “PI3K/Akt: getting it right matters,” Oncogene, vol. 27, no. 50, pp. 6473–6488, 2008. View at Publisher · View at Google Scholar · View at PubMed
  28. Q. W. Fan and W. A. Weiss, “Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance,” Current Topics in Microbiology and Immunology, vol. 347, pp. 279–296, 2010. View at Google Scholar
  29. C. Hartmann, B. Hentschel, W. Wick et al., “Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas,” Acta Neuropathologica, pp. 1–12, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. P. Korkolopoulou, G. Levidou, E. A. El-Habr et al., “Phosphorylated 4E-Binding Protein (p-4E-BP1): a novel prognostic marker in human astrocytomas,” Histopathology. In press.
  31. J. Woenckhaus, K. Steger, K. Sturm, K. Münstedt, F. E. Franke, and I. Fenic, “Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer,” Virchows Archiv, vol. 450, no. 4, pp. 387–395, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. A. Shah, W. A. Swain, D. Richardson et al., “Phospho-Akt expression is associated with a favorable outcome in non-small cell lung cancer,” Clinical Cancer Research, vol. 11, no. 8, pp. 2930–2936, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. R. T. Abraham, “PI 3-kinase related kinases: ‘big’ players in stress-induced signaling pathways,” DNA Repair, vol. 3, no. 8-9, pp. 883–887, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. R. T. Abraham and J. J. Gibbons, “The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy,” Clinical Cancer Research, vol. 13, no. 11, pp. 3109–3114, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. S. M. McBride, D. A. Perez, M. Y. Polley et al., “Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival,” Journal of Neuro-Oncology, vol. 97, no. 1, pp. 33–40, 2010. View at Publisher · View at Google Scholar · View at PubMed
  36. R. P. Ermoian, T. Kaprealian, K. R. Lamborn et al., “Signal transduction molecules in gliomas of all grades,” Journal of Neuro-Oncology, vol. 91, no. 1, pp. 19–26, 2009. View at Publisher · View at Google Scholar · View at PubMed
  37. C. C. Hudson, M. Liu, G. G. Chiang et al., “Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin,” Molecular and Cellular Biology, vol. 22, no. 20, pp. 7004–7014, 2002. View at Publisher · View at Google Scholar
  38. O. Meyuhas, “Chapter 1 physiological roles of ribosomal Protein S6: one of its kind,” International Review of Cell and Molecular Biology, vol. 268, pp. 1–37, 2008. View at Publisher · View at Google Scholar · View at PubMed
  39. S. H. Um, D. D'Alessio, and G. Thomas, “Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1,” Cell Metabolism, vol. 3, no. 6, pp. 393–402, 2006. View at Publisher · View at Google Scholar · View at PubMed
  40. F. Vega, L. J. Medeiros, V. Leventaki et al., “Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma,” Cancer Research, vol. 66, no. 13, pp. 6589–6597, 2006. View at Publisher · View at Google Scholar · View at PubMed
  41. C. G. Proud, “Amino acids and mTOR signalling in anabolic function,” Biochemical Society Transactions, vol. 35, no. 5, pp. 1187–1190, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. S. Darb-Esfahani, A. Faggad, A. Noske et al., “Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro,” Journal of Cancer Research and Clinical Oncology, vol. 135, no. 7, pp. 933–941, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. Q. B. She, E. Halilovic, Q. Ye et al., “4E-BP1 Is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in Tumors,” Cancer Cell, vol. 18, no. 1, pp. 39–51, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. L. Dubois, M. G. Magagnin, A. H. G. Cleven et al., “Inhibition of 4E-BP1 sensitizes U87 glioblastoma xenograft tumors to irradiation by decreasing hypoxia tolerance,” International Journal of Radiation Oncology Biology Physics, vol. 73, no. 4, pp. 1219–1227, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. R. D. Rao, A. C. Mladek, J. D. Lamont et al., “Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells,” Neoplasia, vol. 7, no. 10, pp. 921–929, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. E. Galanis, J. C. Buckner, M. J. Maurer et al., “Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a north central cancer treatment group study,” Journal of Clinical Oncology, vol. 23, no. 23, pp. 5294–5304, 2005. View at Publisher · View at Google Scholar · View at PubMed
  47. T. Schmelzle and M. N. Hall, “TOR, a central controller of cell growth,” Cell, vol. 103, no. 2, pp. 253–262, 2000. View at Google Scholar
  48. S. M. Chang, P. Wen, T. Cloughesy et al., “Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme,” Investigational New Drugs, vol. 23, no. 4, pp. 357–361, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. J. N. Sarkaria, E. Galanis, W. Wu et al., “NCCTG phase I trial of temsirolimus (CCI-779) and temozolomide (TMZ) in combination with radiation therapy (RT) in newly diagnosed glioblastoma multiforme (GBM) patients,” Journal of Clinical Oncology, vol. 27, supplement 15, p. 2019, 2009. View at Google Scholar
  50. T. F. Cloughesy, K. Yoshimoto, P. Nghiemphu et al., “Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma,” PLoS Medicine, vol. 5, no. 1, pp. 0139–0151, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. M. S. Neshat, I. K. Mellinghoff, C. Tran et al., “Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 18, pp. 10314–10319, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. K. Podsypanina, R. T. Lee, C. Politis et al., “An inhibitor of mTOR reduces neoplasia and normalizes p70/s6 kinase activity in Pten+/- mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 18, pp. 10320–10325, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. M. Y. Wang, K. V. Lu, S. Zhu et al., “Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells,” Cancer Research, vol. 66, no. 16, pp. 7864–7869, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. L. Doherty, D. C. Gigas, S. Kesari et al., “Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas,” Neurology, vol. 67, no. 1, pp. 156–158, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. P. Therasse, S. G. Arbuck, E. A. Eisenhauer et al., “New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada,” Journal of the National Cancer Institute, vol. 92, no. 3, pp. 205–216, 2000. View at Google Scholar
  56. D. A. Reardon, J. A. Quinn, J. J. Vredenburgh et al., “Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma,” Clinical Cancer Research, vol. 12, no. 3, pp. 860–868, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. S. M. Chang, J. Kuhn, K. Lamborn et al., “Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas (MG) (NABTC 04-02),” Journal of Clinical Oncology, vol. 27, supplement 15, p. A2004, 2009. View at Google Scholar
  58. D. A. Guertin and D. M. Sabatini, “The pharmacology of mTOR inhibition,” Science Signaling, vol. 2, no. 67, p. pe24, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. C. C. Thoreen, S. A. Kang, J. W. Chang et al., “An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1,” Journal of Biological Chemistry, vol. 284, no. 12, pp. 8023–8032, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  60. J. M. Stommel, A. C. Kimmelman, H. Ying et al., “Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies,” Science, vol. 318, no. 5848, pp. 287–290, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  61. R. G. W. Verhaak, K. A. Hoadley, E. Purdom et al., “Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1,” Cancer Cell, vol. 17, no. 1, pp. 98–110, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  62. J. S. Eshleman, B. L. Carlson, A. C. Mladek, B. D. Kastner, K. L. Shide, and J. N. Sarkaria, “Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy,” Cancer Research, vol. 62, no. 24, pp. 7291–7297, 2002. View at Google Scholar · View at Scopus
  63. M. W. Ronellenfitsch, J. P. Steinbach, and W. Wick, “Epidermal growth factor receptor and mammalian target of rapamycin as therapeutic targets in malignant glioma: current clinical status and perspectives,” Targeted Oncology, vol. 5, no. 3, pp. 183–191, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  64. D. A. Guertin and D. M. Sabatini, “The pharmacology of mTOR inhibition,” Science Signaling, vol. 2, no. 67, p. pe24, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus